Fairvalue-Calculator Fairvalue-Calculator
EN DE

Imed Infinity Medical-Limited Partnership (IMED) Fair Value & Analysis

Healthcare · Il · Market cap 8.0M ILA

Price1.17 ILA
Fair Value0.1700 ILA
Upside-85.5%
Quality76/100
Evidence: Low Range 0.1100 ILA – 0.2100 ILA

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Imed Infinity Medical-Limited Partnership (IMED) currently trades at 1.17 ILA, while our model-based Fair Value estimate is 0.1700 ILA — implying the stock looks roughly 85.5% overvalued today. We read business quality at 76/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Imed Infinity Medical-Limited Partnership engages in research and development and invests in projects in the medical field in Israel. The company's products include Genoox, a platform for gathering genetic data; biobeat medical smartmonitoring, which provides wireless patient monitoring solutions for both clinical and at-home use; Polaris Quantum Biotech, a system for the computerized design of drugs using quantum computers; and Cynerio, which focuses on ensuring patient safety and data protection by securing the connected medical device ecosystem. It also provides Theranica, which provides migraine treatment through neuromodulation; CytoReason, a computer system that performs modeling of the human body; and Nanomedic, a portable electrospinning device for the treatment and healing of complex burns and wounds. Imed Infinity Medical-Limited Partnership was incorporated in 2020 and is based in Tel Aviv-Yafo, Israel.

Open the full interactive analysis →

Similar stocks

Veeva Systems Inc (VEEV) -35% Pro Medicus Limited (PME) -86% BrightSpring Health Services, Inc (BTSG) -68% Tempus AI, Inc (TEM) -74% HealthEquity, Inc (HQY) -33% M3, Inc (MTHRY) +48%

Frequently asked questions

Is Imed Infinity Medical-Limited Partnership (IMED) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 0.1700 ILA versus a price of 1.17 ILA — about −86% (overvalued). Model-based estimate, not financial advice.
What is the fair value of IMED?
Our 21-model fair value for Imed Infinity Medical-Limited Partnership is 0.1700 ILA (as of Jun 25, 2026), built from audited fundamentals. The current price is 1.17 ILA.
What is the quality score of IMED?
Imed Infinity Medical-Limited Partnership has a Quality Score of 76/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.